ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,965Medicare Part D Prescriptions Filled, Including Refills

Rank: 198 out of 680

$570K Total Retail Price of All Prescriptions

Rank: 236 out of 680

490 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

16% of this provider’s 490 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 9,853 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
AMLODIPINE BESYLATE 558 515 1 1
LEVOTHYROXINE SODIUM 446 424 2 2
OMEPRAZOLE 412 357 3 7
SIMVASTATIN 351 334 4 3
LOSARTAN POTASSIUM 318 310 5 21
ATENOLOL 285 247 6 19
FUROSEMIDE 282 257 7 6
HYDROCODONE-ACETAMINOPHEN 265 205 S3 8 4
GABAPENTIN 249 207 9 15
LISINOPRIL 226 215 10 5
ATORVASTATIN CALCIUM 223 207 11 11
PRAVASTATIN SODIUM 200 184 12 10
SYNTHROID 192 187 13 38
METFORMIN HCL 190 165 14 8
METFORMIN HCL ER 176 169 15 54
METOPROLOL SUCCINATE 173 157 16 13
LOVASTATIN 160 135 17 44
CITALOPRAM HBR 157 134 18 22
HYDROCHLOROTHIAZIDE 135 117 19 9
LOSARTAN-HYDROCHLOROTHIAZIDE 132 109 20 51
FLUTICASONE PROPIONATE 129 118 21 41
FENOFIBRATE 129 112 21 66
CLOPIDOGREL 128 117 23 26
SERTRALINE HCL 116 102 24 28
NEXIUM 114 79 25 16
ZOLPIDEM TARTRATE 111 99 26 17
CRESTOR 110 107 27 25
TRIAMTERENE-HCTZ 102 89 28 52
ESCITALOPRAM OXALATE 100 94 29 45
PLAVIX 98 89 30 39
FLUOXETINE HCL 83 81 31 74
BUMETANIDE 79 76 32 102
CYMBALTA 79 72 32 46
QUINAPRIL HCL 78 61 34 104
PANTOPRAZOLE SODIUM 77 71 35 30
TRAMADOL HCL 77 76 35 18
LIPITOR 77 58 35 68
PEN NEEDLE 77 75 35 122
GLIMEPIRIDE 76 68 39 29
POTASSIUM CHLORIDE 76 54 39 14
LANTUS SOLOSTAR 75 63 41 84
MELOXICAM 74 57 42 24
CIPROFLOXACIN HCL 71 68 43 57
ALENDRONATE SODIUM 69 69 44 32
NAMENDA 66 66 45 35
CLONIDINE HCL 63 30 46 36
BUPROPION XL 62 37 47 161
DONEPEZIL HCL 61 61 48 27
DOXYCYCLINE HYCLATE 58 55 49 95
DOXAZOSIN MESYLATE 55 55 50 73
JANUVIA 54 52 51 60
WARFARIN SODIUM 52 52 52 20
LEVOFLOXACIN 50 41 53 97
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 3, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.